XCancer

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Description:

This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that they show up better on the PET scan. Systemic therapy (including enzalutamide) can cause more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells resist hormone therapies. If researchers can find a better way to detect whether glucocorticoid receptors are increasing during therapy, it may lead to more successful therapies using glucocorticoid receptor antagonists.

Sponsor:

University of California, San Francisco

Phase:

Phase 1

Contacts:

Rahul Aggarwal, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT04927663 - Click here to see study on

ClinicalTrials.gov

YJH08

Isotope(s):
Target(s):
  • Glucocorticoid Receptor
Ligand Class: Small Molecules
Inclusion
  • Disease characteristics by cohort, as defined by:
  • COHORT C: Metastatic advanced solid tumor malignancy other than prostate adenocarcinoma with at least one metastasis on conventional imaging.
  • COHORT A: Histologically confirmed metastatic solid tumor malignancy.
  • COHORT B: Metastatic castration-resistant prostate cancer with progression on systemic therapies by Prostate Specific Antigen Working Group 3 (PSAWG3).
Exclusion
  • History of Cushing's disease or Cushing's syndrome.
  • History of adrenal insufficiency requiring use of systemic glucocorticoid replacement.